Trade Mark Journal No.2026/021 22 May 2026

UK00004381329 30 April 2026 (5,42)

Image for mark UK00004381329
International priority date claimed: 5 January 2026 (European Union Intellectual Property Office (EUIPO)) (EU019299204)
Class 5
Pharmaceutical preparations; pharmaceutical and biopharmaceutical preparations based on nucleic acid molecules, antisense nucleic acid molecules, oligonucleotides, antisense oligonucleotides, polynucleotides, DNA, RNA; medical preparations for therapeutic purposes; biological, chemical and biochemical reagents for medical use; biological therapeutic agents, namely molecularly engineered RNA; DNA, RNA, oligonucleotides, antisense oligonucleotides, polynucleotides for medical use; gene editing enzymes for medical use; gene therapy products for medical use; preparations for genetically modifying human or animal cells for medical purposes; medical preparations containing therapeutic DNA and RNA; vaccines.
Class 42
Scientific and industrial research and analysis in the field of life sciences; pharmaceutical and biopharmaceutical drug development services; research and development in the field of biotechnology, gene therapies and pharmaceuticals; medical research laboratory services; providing scientific research information in the field of DNA and RNA therapeutics; providing a website featuring medical information and medical research; clinical trials; scientific and medical research and development in the field of gene therapy and gene expression systems; providing a website featuring information in the field of gene therapy research; consultancy and advisory services related to research and development in the fields of medicine, vaccines, biotechnology and gene therapy.

Cora Biosciences Limited

Representative: Stratagem Intellectual Property Management Limited